DOI QR코드

DOI QR Code

The role of Purkinje cell-derived VEGF in cerebellar astrogliosis in Niemann-Pick type C mice

  • Park, Min Hee (Stem Cell Neuroplasticity Research Group, Kyungpook National University) ;
  • Lee, Ju Youn (Stem Cell Neuroplasticity Research Group, Kyungpook National University) ;
  • Jeong, Min Seock (Stem Cell Neuroplasticity Research Group, Kyungpook National University) ;
  • Jang, Hyung Sup (Stem Cell Neuroplasticity Research Group, Kyungpook National University) ;
  • Endo, Shogo (Aging Neuroscience Research Team, Tokyo Metropolitan Institute of Gerontology) ;
  • Bae, Jae-sung (Stem Cell Neuroplasticity Research Group, Kyungpook National University) ;
  • Jin, Hee Kyung (Stem Cell Neuroplasticity Research Group, Kyungpook National University)
  • Received : 2017.08.26
  • Accepted : 2017.10.20
  • Published : 2018.02.28

Abstract

Niemann-Pick type C disease (NP-C) is a fatal neurodegenerative disorder caused by a deficiency of NPC1 gene function, which leads to severe neuroinflammation such as astrogliosis. While reports demonstrating neuroinflammation are prevalent in NP-C, information about the onset and progression of cerebellar astrogliosis in this disorder is lacking. Using gene targeting, we generated vascular endothelial growth factor (VEGF) conditional null mutant mice. Deletion of VEGF in cerebellar Purkinje neurons (PNs) led to a significant increase of astrogliosis in the brain of NP-C mice in addition to the loss of PNs, suggesting PN-derived VEGF as an important factor in NP-C pathology. Moreover, replenishment of VEGF in neurons improved brain pathology in NP-C mice. Overall, our data provide a new pathological perspective on cerebellar astrogliosis in NP-C and suggest the importance of VEGF as a therapeutic target for this disease.

Keywords

Cerebellar astrogliosis;Niemann-Pick type C disease;Purkinje neuron;Vascular endothelial growth factor

Acknowledgement

Supported by : Korea Health Industry Development Institute (KHIDI), National Research Foundation of Korea (NRF)

References

  1. Vanier MT and Millat G (2003) Niemann-Pick disease type C. Clin Genet 64, 269-281 https://doi.org/10.1034/j.1399-0004.2003.00147.x
  2. Lee H, Lee JK, Park MH et al (2014) Pathological roles of the VEGF/SphK pathway in Niemann-Pick type C neurons. Nat Commun 5, 5514 https://doi.org/10.1038/ncomms6514
  3. Pentchev PG, Comly ME, Kruth HS et al (1985) A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proc Natl Acad Sci U S A 82, 8247-8251 https://doi.org/10.1073/pnas.82.23.8247
  4. Karten B, Vance DE, Campenot RB and Vance JE (2002) Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J Neurochem 83, 1154-1163 https://doi.org/10.1046/j.1471-4159.2002.01220.x
  5. Sarna JR, Larouche M, Marzban H, Sillitoe RV, Rancourt DE and Hawkes R (2003) Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease. J Comp Neurol 456, 279-291 https://doi.org/10.1002/cne.10522
  6. Bae JS, Furuya S, Ahn SJ, Yi SJ, Hirabayashi Y and Jin HK (2005) Neuroglial activation in Niemann-Pick Type C mice is suppressed by intracerebral transplantation of bone marrow-derived mesenchymal stem cells. Neurosci Lett 381, 234-236 https://doi.org/10.1016/j.neulet.2005.02.029
  7. Zhang XM, Ng AH, Tanner JA et al (2004) Highly restricted expression of Cre recombinase in cerebellar Purkinje cells. Genesis 40, 45-51 https://doi.org/10.1002/gene.20062
  8. Elrick MJ, Pacheco CD, Yu T et al (2010) Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum Mol Genet 19, 837-847 https://doi.org/10.1093/hmg/ddp552
  9. Lange C, Storkebaum E, de Almodovar CR, Dewerchin M and Carmeliet P (2016) Vascular endothelial growth factor: a neurovascular target in neurological diseases. Nat Rev Neurol 12, 439-454
  10. Licht T, Goshen I, Avital A et al (2011) Reversible modulations of neuronal plasticity by VEGF. Proc Natl Acad Sci U S A 108, 5081-5086 https://doi.org/10.1073/pnas.1007640108
  11. Giaume C, Kirchhoff F, Matute C, Reichenbach A and Verkhratsky A (2007) Glia: the fulcrum of brain diseases. Cell Death Differ 14, 1324-1335 https://doi.org/10.1038/sj.cdd.4402144
  12. Nimmerjahn A (2009) Astrocytes going live: advances and challenges. J Physiol 587, 1639-1647 https://doi.org/10.1113/jphysiol.2008.167171
  13. Baudry M, Yao Y, Simmons D, Liu J and Bi X (2003) Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp Neurol 184, 887-903 https://doi.org/10.1016/S0014-4886(03)00345-5
  14. German DC, Liang CL, Song T, Yazdani U, Xie C and Dietschy JM (2002) Neurodegeneration in the Niemann- Pick C mouse: glial involvement. Neuroscience 109, 437-450 https://doi.org/10.1016/S0306-4522(01)00517-6
  15. Patel SC, Suresh S, Kumar U et al (1999) Localization of Niemann-Pick C1 protein in astrocytes: implications for neuronal degeneration in Niemann- Pick type C disease. Proc Natl Acad Sci U S A 96, 1657-1662 https://doi.org/10.1073/pnas.96.4.1657
  16. Lopez ME, Klein AD, Dimbil UJ and Scott MP (2011) Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder. J Neurosci 31, 4367-4378 https://doi.org/10.1523/JNEUROSCI.5981-10.2011
  17. Yu T, Shakkottai VG, Chung C and Lieberman AP (2011) Temporal and cell-specific deletion establishes that neuronal Npc1 deficiency is sufficient to mediate neurodegeneration. Hum Mol Genet 20, 4440-4451 https://doi.org/10.1093/hmg/ddr372
  18. Vanier MT (2010) Niemann-Pick disease type C. Orphanet J Rare Dis 5, 16 https://doi.org/10.1186/1750-1172-5-16
  19. Davidson CD, Ali NF, Micsenyi MC et al (2009) Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4, e6951 https://doi.org/10.1371/journal.pone.0006951
  20. Lopez AM, Terpack SJ, Posey KS, Liu B, Ramirez CM and Turley SD (2014) Systemic administration of 2-hydroxypropyl-${\beta}$-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function. Clin Exp Pharmacol Physiol 41, 780-787 https://doi.org/10.1111/1440-1681.12285
  21. Camargo F, Erickson RP, Garver WS et al (2001) Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci 70, 131-142 https://doi.org/10.1016/S0024-3205(01)01384-4
  22. Hovakimyan M, Maass F and Petersen J (2013) Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice. Neuroscience 252, 201-211 https://doi.org/10.1016/j.neuroscience.2013.08.001
  23. Williams IM, Wallom KL, Smith DA, Al Eisa N, Smith C, Platt FM (2014) Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice. Neurobiol Dis 67, 9-17 https://doi.org/10.1016/j.nbd.2014.03.001
  24. Gerber HP, Hillan KJ, Ryan AM et al (1999) VEGF is required for growth and survival in neonatal mice. Development 126, 1149-1159
  25. Wang Y, Kilic E, Kilic U et al (2005) VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 128, 52-63
  26. Tabata T, Sawada S, Araki K, Bono Y, Furuya S and Kano M (2000) A reliable method for culture of dissociated mouse cerebellar cells enriched for Purkinje neurons. J Neurosci Methods 104, 45-53 https://doi.org/10.1016/S0165-0270(00)00323-X